2025
Surgical Management of Breast Cancer Liver Metastasis
Rahnemai-Azar A, Selby L, Lustberg M, Pawlik T. Surgical Management of Breast Cancer Liver Metastasis. Hematology/Oncology Clinics Of North America 2025, 39: 25-35. PMID: 39510675, DOI: 10.1016/j.hoc.2024.08.012.Peer-Reviewed Original ResearchConceptsBreast cancer liver metastasesSystemic chemotherapyHepatic resectionAblation therapyIsolated breast cancer liver metastasesLong-term outcomes of womenProlonged disease-free intervalLocal-regional therapyCancer liver metastasesDisease-free intervalOutcomes of womenBreast cancer metastasisLong-term outcomesRegional therapyLiver metastasesOverall survivalSurgery benefitMultidisciplinary settingCancer metastasisPatientsResectionChemotherapyMetastasisTherapySurgery
2024
The survival benefit of adjuvant trastuzumab with or without chemotherapy in the management of small (T1mic, T1a, T1b, T1c), node negative HER2+ breast cancer
Johnson K, Ni A, Quiroga D, Pariser A, Sudheendra P, Williams N, Sardesai S, Cherian M, Stover D, Gatti-Mays M, Ramaswamy B, Lustberg M, Jhawar S, Skoracki R, Wesolowski R. The survival benefit of adjuvant trastuzumab with or without chemotherapy in the management of small (T1mic, T1a, T1b, T1c), node negative HER2+ breast cancer. Npj Breast Cancer 2024, 10: 49. PMID: 38898072, PMCID: PMC11187074, DOI: 10.1038/s41523-024-00652-4.Peer-Reviewed Original ResearchInvasive disease-free survivalHER2+ breast cancerAdjuvant trastuzumabOverall survivalLocoregional therapyUnivariate analysisBreast cancerBenefit of adjuvant trastuzumabBenefits of adjuvant systemic therapyMulti-institutional retrospective analysisAdjuvant systemic therapyCompare survival outcomesDisease-free survivalTrastuzumab monotherapyNode-negativeSystemic therapyCombination therapySurvival benefitStatistically significant improvementSurvival outcomesRetrospective analysisMultivariate analysisPrimary outcomeTrastuzumabTherapyOutcomes with trastuzumab deruxtecan (T-DXd) by HER2 status and line of treatment in a large real-world database of patients with metastatic breast cancer.
Tarantino P, Lee D, Foldi J, Soulos P, Gross C, Grinda T, Winer E, Lin N, Krop I, Tolaney S, Lustberg M, Sammons S. Outcomes with trastuzumab deruxtecan (T-DXd) by HER2 status and line of treatment in a large real-world database of patients with metastatic breast cancer. Journal Of Clinical Oncology 2024, 42: 1077-1077. DOI: 10.1200/jco.2024.42.16_suppl.1077.Peer-Reviewed Original ResearchReal-world progression-free survivalLines of therapyMetastatic breast cancerMedian real-world progression-free survivalT-DXdHER2+Overall survivalHER2-lowHER2- patientsBreast cancerHER2- metastatic breast cancerTreat metastatic breast cancerProgression-free survivalKaplan-Meier methodLines of treatmentDatabase of patientsRetrospective observational studyClinical trial settingHER2 casesIHC 0Trastuzumab deruxtecanHR statusHER2 statusTriple-negativeMedian ageLong-Term Considerations for Young Breast Cancer Patients: Fertility, Sexual Health, and Quality of Life
Proussaloglou E, Lustberg M. Long-Term Considerations for Young Breast Cancer Patients: Fertility, Sexual Health, and Quality of Life. Current Breast Cancer Reports 2024, 16: 227-236. DOI: 10.1007/s12609-024-00548-z.Peer-Reviewed Original ResearchYoung breast cancer patientsSurvivorship careBreast cancer patientsEffectiveness of cancer careFamily planning concernsPost-partum careUnique survivorship needsQuality-of-life issuesBreast cancerQuality of lifeCancer patientsSurvivorship needsGenitourinary syndrome of menopauseCancer careDisease-free recurrenceAnti-estrogen therapyUnique group of patientsSexual healthGroup of patientsCareVaginal estrogenEndocrine therapyOverall survivalSummaryAdditional researchIatrogenic menopause
2023
Stereotactic Radiosurgery for Women Older than 65 with Breast Cancer Brain Metastases
Upadhyay R, Klamer B, Perlow H, White J, Bazan J, Jhawar S, Blakaj D, Grecula J, Arnett A, Mestres-Villanueva M, Healy E, Thomas E, Chakravarti A, Raval R, Lustberg M, Williams N, Palmer J, Beyer S. Stereotactic Radiosurgery for Women Older than 65 with Breast Cancer Brain Metastases. Cancers 2023, 16: 137. PMID: 38201564, PMCID: PMC10778270, DOI: 10.3390/cancers16010137.Peer-Reviewed Original ResearchIntracranial progression-free survivalProgression-free survivalBreast cancer patientsBrain metastasesOverall survivalYounger patientsCancer patientsRadiation necrosisOlder womenOlder patientsPositive diseaseSystemic therapyMultivariable analysisTreatment patternsBiopsy-proven breast cancer patientsCox proportional hazards regression methodsIncidence of BMOlder breast cancer patientsSingle-institutional retrospective reviewTreatment-related adverse eventsAge groupsBreast cancer brain metastasesMetastatic breast cancer patientsWorse progression-free survivalProportional hazards regression methods
2021
Supportive Care: Low Cost, High Value.
Popescu RA, Roila F, Arends J, Metro G, Lustberg M. Supportive Care: Low Cost, High Value. American Society Of Clinical Oncology Educational Book 2021, 41: 1-11. PMID: 33830830, DOI: 10.1200/edbk_320041.Peer-Reviewed Original ResearchConceptsQuality of lifePhysical exerciseChemotherapy-induced peripheral neuropathyLarge phase III trialsElectronic patient-reported outcome measuresPatient-reported outcome measuresPersonalization of chemotherapySupportive care unitPhase III trialsSupportive care interventionsCancer-related fatigueMind-body interventionsNonpharmacologic strategiesScrambler therapyGastrointestinal dysmotilityIII trialsOverall survivalSupportive careTreatable causeMuscle trainingPeripheral neuropathyCare unitClinic appointmentsMetabolic derangementsRegular screeningSurvival outcomes in patients with IDC and ILC breast cancer: A well matched single institution study.
Grimm M, Ramaswamy B, Lustberg M, Wesolowski R, Sardesai S, VanDeusen J, Cherian M, Stover D, Gatti-Mays M, Pariser A, Kassem M, Stephens J, Palettas M, Williams N. Survival outcomes in patients with IDC and ILC breast cancer: A well matched single institution study. Journal Of Clinical Oncology 2021, 39: e13056-e13056. DOI: 10.1200/jco.2021.39.15_suppl.e13056.Peer-Reviewed Original ResearchFirst-line endocrine therapyProgression-free survivalInvasive lobular carcinomaMedian progression-free survivalEndocrine therapyMedian overall survivalOverall survivalBreast cancerDuctal cancerLobular cancerEstrogen receptor/progesterone receptorMetastatic invasive lobular carcinomaOhio State University Comprehensive Cancer CenterDistinct clinicopathologic characteristicsInitial endocrine therapyInitiation of chemotherapyYear of diagnosisKaplan-Meier methodMetastatic breast cancerSite of metastasisInvasive breast cancerSingle-institution studyComprehensive cancer centerLine endocrine therapyConcerns of resistance
2020
Surgical Management of Breast Cancer Liver Metastasis
Rahnemai-Azar AA, Selby LV, Lustberg MB, Pawlik TM. Surgical Management of Breast Cancer Liver Metastasis. Surgical Oncology Clinics Of North America 2020, 30: 27-37. PMID: 33220807, DOI: 10.1016/j.soc.2020.09.003.Peer-Reviewed Original ResearchConceptsBreast cancer liver metastasesCancer liver metastasesSystemic chemotherapyHepatic resectionLiver metastasesAblative therapyProlonged disease-free intervalDisease-free intervalBetter overall survivalLong-term outcomesLocal-regional therapyEffective systemic chemotherapyBreast cancer metastasisLimited diseaseOverall survivalRegional therapySurgical managementSurgery benefitMultidisciplinary settingPatientsCancer metastasisMetastasisTherapyResectionChemotherapyA phase Ib study of the safety and pharmacology of nilotinib to prevent paclitaxel-induced peripheral neuropathy in patients with breast cancer.
Adams E, Lustberg M, Jin Y, Li Y, Sparreboom A, Hu S. A phase Ib study of the safety and pharmacology of nilotinib to prevent paclitaxel-induced peripheral neuropathy in patients with breast cancer. Journal Of Clinical Oncology 2020, 38: tps12128-tps12128. DOI: 10.1200/jco.2020.38.15_suppl.tps12128.Peer-Reviewed Original ResearchChemotherapy-induced peripheral neuropathyPaclitaxel infusionFree survivalPeripheral neuropathyBreast cancerPaclitaxel-induced peripheral neuropathyBreast cancer stage IEarly-stage breast cancerGrade 2 neuropathyPhase Ib studyPhase II doseDisease-free survivalCancer stage IStage breast cancerBreast cancer therapyTyrosine kinase inhibitorsQuality of lifeOrganic anion transportingOATP1B1 inhibitionOral nilotinibWeekly paclitaxelPaclitaxel dosePaclitaxel therapyOverall survivalWeekly doses
2019
LPTO-10. ASSESSMENT OF LEPTOMENINGEAL CARCINOMATOSIS DIAGNOSIS AND OUTCOMES FROM 2005 TO 2015 AT THE OHIO STATE UNIVERSITY
Williams N, Rinehardt H, Morgan E, Kassem M, Palettas M, Puduvalli V, Giglo P, Lustberg M, Wesolowski R, Sardesai S, Stover D, Vandeusen J, Bazan J, Ramaswamy B, Noonan A. LPTO-10. ASSESSMENT OF LEPTOMENINGEAL CARCINOMATOSIS DIAGNOSIS AND OUTCOMES FROM 2005 TO 2015 AT THE OHIO STATE UNIVERSITY. Neuro-Oncology Advances 2019, 1: i8-i8. PMCID: PMC7213376, DOI: 10.1093/noajnl/vdz014.033.Peer-Reviewed Original ResearchDiagnosis of LCMagnetic resonance imagingLeptomeningeal carcinomatosisLMC diagnosisOverall survivalPrimary cancerOhio State University Comprehensive Cancer CenterSingle-institution retrospective studyCentral nervous system malignanciesMedian overall survivalStage II diseaseStage III diseaseStage IV diseaseKaplan-Meier methodPrimary breast cancerSurvival of patientsNervous system malignanciesCerebrospinal fluid cytologySolid tumor malignanciesConfirmation of diagnosisComprehensive cancer centerClinical characteristicsMedian ageMRI findingsInitial diagnosisSurvival outcomes by hormone receptor expression in early-stage HER2-positive breast cancer.
Sardesai S, Kassem M, Morgan E, Palettas M, Stephens J, Williams N, Stover D, Van Deusen J, Wesolowski R, Lustberg M, Ramaswamy B. Survival outcomes by hormone receptor expression in early-stage HER2-positive breast cancer. Journal Of Clinical Oncology 2019, 37: e12050-e12050. DOI: 10.1200/jco.2019.37.15_suppl.e12050.Peer-Reviewed Original ResearchDisease-free survivalPositive breast cancerHormone receptor expressionOverall survivalBreast cancerReceptor expressionPositive diseaseTumor gradeEarly-stage HER2-positive breast cancerOhio State University Comprehensive Cancer CenterSecond primary breast cancerSingle-institution retrospective analysisHER2-positive breast cancerAdjuvant ovarian suppressionHR-negative diseaseHR-negative patientsHR-positive diseaseTriple-positive diseaseAnti-estrogen therapyComplete pathologic responseSingle institution experienceKaplan-Meier methodPrimary breast cancerInvasive ductal cancerLow tumor gradeAssessment of Leptomeningeal Carcinomatosis Diagnosis and Outcomes from 2005 to 2015 at Ohio State University.
Rinehardt H, Morgan E, Kassem M, Palettas M, Miah A, Alnahhas I, Guillermo Prieto Eibl P, Suresh A, Ganju A, Williams N, Puduvalli V, Giglio P, Lustberg M, Wesolowski R, Sardesai S, Stover D, Vandeusen J, Bazan J, Ramaswamy B, Noonan A. Assessment of Leptomeningeal Carcinomatosis Diagnosis and Outcomes from 2005 to 2015 at Ohio State University. Journal Of Clinical Oncology 2019, 37: e13554-e13554. DOI: 10.1200/jco.2019.37.15_suppl.e13554.Peer-Reviewed Original ResearchDiagnosis of LCMagnetic resonance imagingLeptomeningeal carcinomatosisLMC diagnosisOverall survivalMRI findingsPrimary cancerLung cancerBreast cancerOhio State University Comprehensive Cancer CenterStage IV breast cancerSingle-institution retrospective studyCentral nervous system malignanciesMedian overall survivalStage II diseaseStage III diseaseStage IV diseaseHigh-risk patientsKaplan-Meier methodPrimary breast cancerSurvival of patientsNervous system malignanciesCerebrospinal fluid cytologyConfirmation of diagnosisComprehensive cancer centerThe Global POLAR program: Two pivotal placebo-controlled studies of calmangafodipir used on top of modified FOLFOX6 to prevent chemotherapy-induced peripheral neuropathy (CIPN).
Lustberg M, Pfeiffer P, Qvortrup C, Muro K, Bengtson M, Nittve M, Sonesson C, Nagahama F, Sonehara Y, Carlsson C. The Global POLAR program: Two pivotal placebo-controlled studies of calmangafodipir used on top of modified FOLFOX6 to prevent chemotherapy-induced peripheral neuropathy (CIPN). Journal Of Clinical Oncology 2019, 37: tps3616-tps3616. DOI: 10.1200/jco.2019.37.15_suppl.tps3616.Peer-Reviewed Original ResearchChemotherapy-induced peripheral neuropathyChronic chemotherapy-induced peripheral neuropathyMetastatic colorectal cancerProportion of patientsFree survivalSafety endpointCumulative doseHigh-risk stage IIAdditional safety endpointsProgressive-free survivalCommon adverse eventsPlacebo-controlled studyDisease-free survivalOxaliplatin-induced neuropathyTreatment of patientsManganese superoxide dismutase activitySuperoxide dismutase mimeticFOLFOX6 chemotherapyMFOLFOX6 chemotherapyOXA treatmentPrimary endpointAdverse eventsFirst doseOverall survivalMS patientsCLO19-027: Assessment of Metastatic Invasive Lobular Carcinoma Management and Outcomes From 2004-2014: A Single Institution Experience
Boutrid H, Lustberg M, Vandeusen J, Sardesai S, Stover D, Wesolowski R, Cherian M, Stephens J, Palettas M, Morgan E, Kassem M, Berger M, Vargo C, Ramaswamy B, Williams N. CLO19-027: Assessment of Metastatic Invasive Lobular Carcinoma Management and Outcomes From 2004-2014: A Single Institution Experience. Journal Of The National Comprehensive Cancer Network 2019, 17: clo19-027. DOI: 10.6004/jnccn.2018.7251.Peer-Reviewed Original ResearchMetastatic invasive lobular carcinomaProgression-free survivalInvasive lobular carcinomaFirst-line treatment groupEndocrine therapyFirst-line treatmentOverall survivalCDK 4/6 inhibitorsMetastatic settingBone metastasesTreatment groupsMedian progression-free survivalOhio State University Comprehensive Cancer CenterInvasive breast cancer casesOnly bone metastasesMedian overall survivalFirst-line therapyWidespread metastatic diseaseKaplan-Meier methodRetrospective chart reviewSingle institution experienceInvasive ductal cancerKaplan-Meier curvesPreferred treatment optionAppropriate clinical contextThe Global POLAR program: Calmangafodipir used on top of modified FOLFOX6 (5-FU/FA and oxaliplatin) to prevent chemotherapy induced peripheral neuropathy (CIPN).
Pfeiffer P, Qvortrup C, Muro K, Lustberg M, Nagahama F, Sonehara Y, Bengtson M, Nittve M, Sonesson C, Carlsson C. The Global POLAR program: Calmangafodipir used on top of modified FOLFOX6 (5-FU/FA and oxaliplatin) to prevent chemotherapy induced peripheral neuropathy (CIPN). Journal Of Clinical Oncology 2019, 37: tps722-tps722. DOI: 10.1200/jco.2019.37.4_suppl.tps722.Peer-Reviewed Original ResearchMetastatic colorectal cancerProportion of patientsFree survivalSafety endpointCumulative doseHigh-risk stage IIAdditional safety endpointsProgressive-free survivalCommon adverse eventsOxaliplatin-induced neuropathyDisease-free survivalPatient reported symptomsTreatment of patientsManganese superoxide dismutase activitySuperoxide dismutase mimeticFOLFOX6 chemotherapyMFOLFOX6 chemotherapyOXA treatmentPrimary endpointAdverse eventsFirst doseOverall survivalMS patientsPeripheral neuropathyTreatment breaks
2014
Heterogeneous atypical cell populations are present in blood of metastatic breast cancer patients
Lustberg M, Balasubramanian P, Miller B, Garcia-Villa A, Deighan C, Wu Y, Carothers S, Berger M, Ramaswamy B, Macrae E, Wesolowski R, Layman R, Mrozek E, Pan X, Summers T, Shapiro C, Chalmers J. Heterogeneous atypical cell populations are present in blood of metastatic breast cancer patients. Breast Cancer Research 2014, 16: r23. PMID: 24602188, PMCID: PMC4053256, DOI: 10.1186/bcr3622.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntigens, CDAntigens, Differentiation, MyelomonocyticAntigens, NeoplasmBiomarkers, TumorBreast NeoplasmsCell Adhesion MoleculesCell Line, TumorEpithelial Cell Adhesion MoleculeErbB ReceptorsFemaleFlow CytometryHumansImmunohistochemistryKeratin-18Keratin-19Keratin-8Leukocyte Common AntigensMCF-7 CellsMicroscopy, ConfocalMiddle AgedNeoplasm MetastasisNeoplastic Cells, CirculatingPrognosisProspective StudiesVimentinConceptsMetastatic breast cancerBreast cancer patientsBlood samplesCancer patientsBreast cancerMetastatic breast cancer patientsPatient samplesMultiparametric flow cytometry analysisAtypical cell populationNumber of CKPresent prospective trialWorse overall survivalTumor-associated macrophagesCell populationsPan-hematopoietic marker CD45Confocal microscopyEpidermal growth factor receptorEpithelial cell adhesion moleculeNormal control samplesCell surface markersRole of EpCAMFlow cytometry analysisGrowth factor receptorOverall survivalProspective trial
2012
Phase I/II trial of non-cytotoxic suramin in combination with weekly paclitaxel in metastatic breast cancer treated with prior taxanes
Lustberg M, Pant S, Ruppert A, Shen T, Wei Y, Chen L, Brenner L, Shiels D, Jensen R, Berger M, Mrozek E, Ramaswamy B, Grever M, Au J, Wientjes M, Shapiro C. Phase I/II trial of non-cytotoxic suramin in combination with weekly paclitaxel in metastatic breast cancer treated with prior taxanes. Cancer Chemotherapy And Pharmacology 2012, 70: 49-56. PMID: 22729159, PMCID: PMC3466596, DOI: 10.1007/s00280-012-1887-x.Peer-Reviewed Original ResearchConceptsObjective response rateMetastatic breast cancerWeekly paclitaxelAnti-tumor activityII trialBreast cancerPhase I/II trialMedian progression-free survivalGrowth factorPhase IMedian overall survivalResultsThirty-one patientsPhase II trialProgression-free survivalDose-limiting toxicityBasic fibroblast growth factorPre-specified criteriaNon-cytotoxic dosesFibroblast growth factorPrior taxaneMetastatic settingUnacceptable toxicityOverall survivalPolypeptide growth factorsSuramin concentrations
2007
Optimal Duration of Chemotherapy in Advanced Non-Small Cell Lung Cancer
Lustberg M, Edelman M. Optimal Duration of Chemotherapy in Advanced Non-Small Cell Lung Cancer. Current Treatment Options In Oncology 2007, 8: 38-46. PMID: 17634834, DOI: 10.1007/s11864-007-0020-6.Peer-Reviewed Original ResearchConceptsPlatinum-based chemotherapyQuality of lifeLung cancerNew agentsAdvanced non-small cell lung cancerOptimal durationNon-small cell lung cancerPlatinum-based combination chemotherapyEpidermal growth factor receptor inhibitorsGrowth factor receptor inhibitorsBenefit of chemotherapyFirst-line chemotherapyAdditional survival benefitAdvanced stage diseaseDuration of therapyMetastatic lung cancerCell lung cancerMatrix metalloproteinase inhibitorsCytotoxic regimenPlatinum doubletsLine chemotherapySequential therapyStage diseaseCombination chemotherapyOverall survival